UNION receives approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19
· Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir · UNION has leveraged existing deep knowledge of niclosamide, derivatives and formulation technologies to rapidly advance a treatment candidate for COVID-19 · The Danish Medicines Agency has approved UNIONs Clinical Trial Application to initiate study with niclosamide in healthy volunteers · The COVID-19 program has been awarded financial support from the Innovation Fund Denmark COPENHAGEN, Denmark: UNION therapeutics A/S (“UNION”), a